We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Bluebird Bio Inc Escrow Line

Sell:0.000000p Buy:0.000000p Change: No change
Market closed |  Prices as at close on 9 June 2025 | Switch to live prices |
Takeover

Bluebird Bio Inc Escrow Line

Type:
Takeover
Shareholder action required:
Yes
Status:
Update Pending
Details (last updated 17 Jun 2025)

The boards of Bluebird Bio Inc and Beacon Merger Sub, Inc, a wholly owned subsidiary of Beacon Midco Inc, which is itself a wholly owned subsidiary of Beacon Parent Holdings L.P, recently announced the terms of a takeover. 

 

Under the terms of the takeover, you have been offered either USD3.00 and 1 Contingent Value Right (CVR), or a cash amount of USD5.00 for each share held. The deadline to accept the takeover offer has been extended.

 

The CVR entitles holders to a payment of USD6.84 if Bluebird's product portfolio achieves USD600 million in net sales within any consecutive 12-month period ending on or before 31 December 2027.

 

If you do not accept the offer, your shares will be redeemed and you will receive the default option of USD3.00 and 1 CVR. Please note the company has not yet announced when the proceeds will be paid.

 

Accept the offer – Act by noon on Thursday 19 June 2025

 

 Any shares you ask to sell will be removed from your portfolio from 19 June 2025. Cash from shares sold will be converted from US Dollars to Pound Sterling upon receipt, based on the prevailing exchange rate at the time and our standard currency conversion fees, and credited to your account.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter/message and not on the summary information outlined above.

×
Sell:0.000000p
Buy:0.000000p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 9 June 2025 | Switch to live prices |
Takeover

Bluebird Bio Inc Escrow Line

Type:
Takeover
Shareholder action required:
Yes
Status:
Update Pending
Details (last updated 17 Jun 2025)

The boards of Bluebird Bio Inc and Beacon Merger Sub, Inc, a wholly owned subsidiary of Beacon Midco Inc, which is itself a wholly owned subsidiary of Beacon Parent Holdings L.P, recently announced the terms of a takeover. 

 

Under the terms of the takeover, you have been offered either USD3.00 and 1 Contingent Value Right (CVR), or a cash amount of USD5.00 for each share held. The deadline to accept the takeover offer has been extended.

 

The CVR entitles holders to a payment of USD6.84 if Bluebird's product portfolio achieves USD600 million in net sales within any consecutive 12-month period ending on or before 31 December 2027.

 

If you do not accept the offer, your shares will be redeemed and you will receive the default option of USD3.00 and 1 CVR. Please note the company has not yet announced when the proceeds will be paid.

 

Accept the offer – Act by noon on Thursday 19 June 2025

 

 Any shares you ask to sell will be removed from your portfolio from 19 June 2025. Cash from shares sold will be converted from US Dollars to Pound Sterling upon receipt, based on the prevailing exchange rate at the time and our standard currency conversion fees, and credited to your account.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter/message and not on the summary information outlined above.

×
Sell:0.000000p
Buy:0.000000p
Change: No change
Market closed |  Prices as at close on 9 June 2025 | Switch to live prices |
Takeover

Bluebird Bio Inc Escrow Line

Type:
Takeover
Shareholder action required:
Yes
Status:
Update Pending
Details (last updated 17 Jun 2025)

The boards of Bluebird Bio Inc and Beacon Merger Sub, Inc, a wholly owned subsidiary of Beacon Midco Inc, which is itself a wholly owned subsidiary of Beacon Parent Holdings L.P, recently announced the terms of a takeover. 

 

Under the terms of the takeover, you have been offered either USD3.00 and 1 Contingent Value Right (CVR), or a cash amount of USD5.00 for each share held. The deadline to accept the takeover offer has been extended.

 

The CVR entitles holders to a payment of USD6.84 if Bluebird's product portfolio achieves USD600 million in net sales within any consecutive 12-month period ending on or before 31 December 2027.

 

If you do not accept the offer, your shares will be redeemed and you will receive the default option of USD3.00 and 1 CVR. Please note the company has not yet announced when the proceeds will be paid.

 

Accept the offer – Act by noon on Thursday 19 June 2025

 

 Any shares you ask to sell will be removed from your portfolio from 19 June 2025. Cash from shares sold will be converted from US Dollars to Pound Sterling upon receipt, based on the prevailing exchange rate at the time and our standard currency conversion fees, and credited to your account.

 

Full details of this event will be sent to Qualifying Hargreaves Lansdown clients by either post or secure message. Please note that any instruction you give must be based on the full details provided in the letter/message and not on the summary information outlined above.

×
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Open:
n/a
Trade high:
n/a
Year high:
n/a
Market capitalisation
Market cap.
:
n/a
Previous close:
n/a
Trade low:
n/a
Year low:
n/a
P/E ratio:
n/a
Previous:
0.00p (0.00%) Previous:
0.00p
Volume:
n/a
Dividend yield:
n/a
EMS:
n/a
Data delayed by at least 15 minutes.
* To buy US shares you must first complete and return a US government ‘W-8BEN’ form.

Share chart Chart

Bluebird Bio Inc performance chart

Performance

Not available for this stock.

Dividend information for this stock is not available.

Dividend information for this stock is not available.

Ready to invest?

Invest now

Want to invest?

To buy shares in , you'll need to have an account.

Explore the options

Important Documents

There are no documents available for this stock.

Company news for this stock is not available.

Company announcements for this stock is not available.

Annual & interim reports

Annual & interim reports are not available for this stock.

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Prices provided by Hargreaves Lansdown. Charts provided by Factset. News and fundamental data provided by Digital Look. Exchange disclaimer

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.